Author Guidelines

1.1 Summary

The Journal of Asian Pacific Society of Cardiology (JAPSC) endeavours to publish unbiased content. All articles must be of an impartial nature.
 

All submissions are assessed by the editor-in-chief with the support of the deputy and associate editors, and guidance from the editorial board.


Following submission, articles are subject to independent double-blind peer review and copy-editing prior to publication. All articles must receive final approval of the editor-in-chief and/or deputy editors before they are published.


Articles must be submitted using our electronic peer review system, Editorial Manager. Please submit here.

If you are interested in submitting a manuscript and wish to discuss it further, or have any editorial queries, please email the editorial contact for the relevant journal: 
ashlynne.merrifield@radcliffe-group.com.

1.2 Benefits of Publishing with Us

Radcliffe Cardiology’s journals aim to support the continuous medical education of both specialist and general cardiologists. We publish original research, review articles, expert opinions pieces and case reports written by leading authorities, addressing the most pertinent developments in their field. Our authors benefit from:
 

Open research

All research published in JAPSC is open access which means the version of record (VOR) is freely accessible to everyone across the globe immediately upon publication. As an author you retain all non-commercial rights for articles published under the Creative Commons Attribution Non-commercial CC-BY-NC 4.0 license, allowing users to read, download, copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.


Quality

We are committed to the highest standards of peer review. JAPSC follows a rigorous double-blind peer review process that is conducted independently and treated confidentially. All articles and the peer review comments received are evaluated by the Editor-in-Chief before they make their decision.


Speed

On average, articles submitted to Radcliffe Cardiology journals receive their first decision in 5 weeks of submission, ensuring rapid review whilst maintaining high quality, rigorous peer review.


Visibility

In order to maximise the reach and impact of your research, we are committed to ensuring every article we publish is promoted as widely as possible. Along with open access, which supports increased readership and citations with no barriers to access, our marketing team with their SEO expertise, will ensure your research is visible to the widest possible audience, including marketing through our social and email channels to our global community of 100,000+registered recipients.


Society Partnerships

The Journal of Asian Pacific Society of Cardiology (JAPSC) is the official journal of the Asian Pacific Society of Cardiology. Radcliffe Cardiology publishes the journal on behalf of the society.   

1.3 Authorship Criteria

All authors involved should be listed and are accountable for the content should it be published and must meet the following conditions to be considered an author:
 

  1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; and
  2. Drafting the work or revising it critically for important intellectual content; and
  3. Final approval of the version to be published; and
  4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.


Those meeting the above criteria are eligible to participate in reviewing and drafting the final manuscript. The corresponding author will be responsible for key communication with the publisher. Those not meeting the above criteria should be acknowledged as a contributor in the acknowledgments section rather than an author. The editor is not held responsible for identifying authors on the manuscript. This information must be supplied at submission.

1.4 Submission Types

Articles accepted for publication include the following content types and may be solicited or unsolicited:

Content Type

Description

Keywords

Word limits (excluding references/abstract)

Misc.

Figs

Tables

Videos

Clinical perspectives

Case report

Present novel findings or strategies on a particular topic to aid diagnosis/treatment/management

7

1500

Max. 10 refs

Abstract to be supplied (max 50 words)

300dpi

Max. 5

tif,.pdf or .jpeg format

Editorial

*by invitation only

An article that reflects on a particular issue, event, methodology, innovation or gap in literature.

7

1500

Max. 15 refs

Not subject to peer-review

 

 

300dpi

Max. 5

tif,.pdf or .jpeg format

Expert opinion

Coverage of topical issues in cardiology from expert in field that will be of interest to readers

7

1500 – 2500

Max. 20 refs

Accompanied by an abstract (max 160 words)

300dpi

Max. 5

tif,.pdf or .jpeg format

Letter to editor

Readers are invited to provide comment on articles for the EiC to read/respond.

7

500

Max. 5 refs

Not subject to peer-review

Review article

Summary and critical evaluation of current research in field and impact on current and future practice.

7

2500 – 5000

Max. 80 refs

Accompanied by an abstract (max 160 words)

300dpi

Max. 5

tif,.pdf or .jpeg

Original

Research

Including clinical research, meta-analyses and translational science

7

2500 – 5000

Max. 100 refs

Accompanied by a structured abstract

(max 250 words)

300dpi

Max. 5

tif,.pdf or .jpeg

1.5 Article Preparation: Checklist Summary
Section Requirement
Submission types
  • Case Reports: 1,500 words excl abstract & refs. Max. 10 references.
  • Editorial: 1500 words excl abstract & refs. Max. 15 references. Editorials are by invitation only. 
  • Expert Opinion: 1,500 – 2500 words excl abstract & ref. Max. 20 references
  • Letter: 500 words. Max 5 references.
  • Review Article: 2,500 – 5,000 words excl abstract & ref. Max. 100 references.
  • Original Research: 2,500 – 5,000 words excl abstract & Ref. Max 100 references.
Manuscript
  • Submitted as word document
  • Continuous line numbering
  • Double spacing
  • Page numbers.
Title page Title: of the article (<300 characters);

Short title (<75 characters);

Author(s) information: full name, position, institution and/or organisation, full contact information: email addresses for all authors and a postal correspondence address for the lead author. We also encourage ORCID identification to be listed.

Disclaimers: a statement of disclosure/conflicts of interest relevant to the article for each author; form for Disclosure of

Potential Conflicts of Interest: www.icmje.org/conflicts-of-interest

Support statements: include grants, equipment, drugs, and /or other support that facilitated conduct of the work

Keywords: a maximum of 7 keywords to be listed

Word count: should be provided for the article and should not include the abstract
Abstract

Reviews and Expert Opinions:

Unstructured, unreferenced. Provides the context of the article. Should summarise the purpose, basic procedure, main findings and key conclusions.

<160 words

Case Reports:

Unstructured, unreferenced. Provides the context of the article. Should summarise the purpose, basic procedure, main findings and key conclusions.

<50 words

Original Research:

Structured including the following headings:

  • Background
  • Methods
  • Results
  • Conclusion
  • Trial Registration
The abstract should present essential data in 5 paragraphs. Use complete sentences. All data in the abstract also must appear in the manuscript text or tables.

< 250 words
Keywords 7
Clinical perspective Summarising the clinical implications of your review in three to five bullet points.
Acknowledgements The author(s) should acknowledge substantive contributions to the article, including assistance, advice, materials and other resources.
Conflicts of interest/disclosures The author(s) should state any conflicts of interest/intellectual property to the article, including any sources of financial support or assistance for work; ensure sponsor names/sponsoring organizations are included and the for-profit interest(s) the sponsor represents, if applicable.

Ensure to highlight if authors had access to the study data.

We make it clear when any research has been funded. If a funded paper, please include the statement: Authors had full access to all data in this study and take full responsibility for the integrity of the data and the accuracy of the data analysis.
Informed consent Authors should include a statement in the manuscript that informed consent was obtained, if experimentation with human subjects was conducted. The privacy rights of human subjects must always be observed. 
Declaration of Helsinki The authors should state that their study complies with the Declaration of Helsinki, that the locally appointed ethics committee has approved the research protocol and that informed consent has been obtained from the subjects (or their legally authorised representative). 
Data Availability Statement Include a data availability statement (DAS) that links to your data. Where the data cannot be shared, you should confirm why it is not possible to share the data within this statement. Please see Section 3.0 for full details of our Data Sharing Policy.
Layout

Reviews, Expert Opinions and Case Reports:

Divide the text under headings and subheadings. Keep these short and succinct (max 5 words) and similar in sense and style.

Original Research:

Must include the following headed sections:

  • Introduction
  • Methods
    • Patient and Public Involvement statement (if relevant)
  • Results
  • Discussion
    • Study limitations
  • Data Availability Statement
Language

All articles should be written in UK English, free from jargon, and the writing should be clear and direct. 


All acronyms and abbreviations must be explained in full at first mention.

Figures, tables, illustrations, screenshots and photographs A maximum of five may be included. Anything over this amount should be supplied as supplementary data. In addition, any Tables that require more than 2 pages, must be supplied as supplementary material.

Figures must be supplied as digital files only (.tiff, .pdf or .jpeg files) and be at least 300 dpi.

Clear and concise titles/captions must be provided, and all symbols and abbreviations used must be defined in a footnote.

All figures must be referred to in the main text.

Figure and table legends must be included in the manuscript after the reference section

All abbreviations in figures must be spelled out in full in the figure caption.

High-resolution images to be provided at revision stages if not supplied at submission.

Tables:

Graphs and tables must be supplied as editable files formatted as a table in Microsoft Word or Excel.

To be added after the reference list.

Authors are responsible for obtaining permission for all copyright material, including tables, figures and images. Please provide licences with submission.
References

In text: All articles must be fully referenced

References must be numbered in order of first mention. They must be indicated in the text by a superscript number with the full list at the end of the article in numerical/chronological order.

Include the first three authors only, followed by et al., unless there are four authors, in which case list all four. Authors must include DOI and PubMed ID. (PubMed IDs can often be imported simply and quickly using a software such as EndNote which most institutions have access to.)

Examples:
 
Journal article: Delpón E, Cordeiro JM, Núñez L, et al. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol 2008;1:209–18. https://doi.org/10.1161/CIRCEP.107.748103; PMID: 19122847.

Book Chapter: Mansbach H. Sumatriptan: looking back and looking forward. In: Humphrey P, Ferari M, Olesen J (eds). The Triptans. New York: Oxford University Press, 2001;183–9.

Permissions Authors are responsible for obtaining permission for all copyrighted material, including tables, figures and images. Permission is required irrespective of ownership. Permission proof is required at the time of submission. Papers cannot be accepted for publication until all necessary permissions are obtained.
Resources When preparing your manuscript, we recommend you consult the following resources to improve the quality of your submission: 

Systematic reviews and meta-analyses: PRISMA guidelines
Case Reports: the CARE case report guidelines 
Clinical trials: CONSORT 
Human Research: Declaration of Helsinki (2013)
Animal studies: ARRIVE
1.6 Permissions

If a figure, table or illustration has been previously published, please ensure the original source is acknowledged as a figure legend and written permission from the copyright holder is sought. All figures/tables must have one of the below statements if they are not original:
 

If it is data taken from and no permissions are required – Data from: XXX et al. YEAR,RefXXX et al. YEAR,RefXXX et al. YEAR.Ref
If it is reproduced – Source: XXX et al. YEAR.Ref Reproduced with permission from PUBLISHER.
If it is adapted – Source: XXX et al. YEAR.
Ref Adapted with permission from PUBLISHER.


Original images that are the authors own and that have not been published elsewhere, do not require permission. If applicable, please indicate this as a legend in your submission. If all images are original, please include a statement to this effect in the manuscript/at submission.


Our journals are open access. Please ensure that open access reuse permission is sought where possible. If it if not, please highlight this by adding ‘This content is not covered by the Creative Commons license of this publication. To reuse, please contact the rights holder.’
 

Authors are responsible for obtaining permission for all copyrighted material, including tables, figures and images. Permission is required irrespective of ownership. Permission proof is required at the time of submission. Papers cannot be accepted for publication until all necessary permissions are sought.

1.7 Declarations: Conflict of Interest and Intellectual Property

A conflict of interest exists when an opinion may be influenced or biased by a secondary interest such as financial gain. Conflicts of interest may occur from commercial or financial interests and/or personal relationships, beliefs and or rivalries such as research funding, consultancy services, serving on speakers’ bureaus, travel expenses, appearance fees, the receipt of share options, or direct employment by a commercial entity.
 

We make it clear in our publications where any conflicts of interest occur and inform readers when research has been funded. All authors, peer reviewers and editors must declare any conflicts of interest pertaining to the article when submitting a manuscript. All sources of support for the work where a conflict exists will be publicised. Conversely, please state clearly should there be no conflicts of interest to declare.


The authors must complete the questions asked in our electronic submission system (Editorial Manager), which follows the ICMJE recommendations. These answers will be stored, and a disclosure statement will appear on every manuscript published within the journal based on your response. The purpose of this statement is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. For more information and to download a Form for Disclosure of Potential Conflicts of Interest, which can be submitted with your manuscript, please visit: https://www.icmje.org/conflicts-of-interest.


Reviewers must declare any conflicts of interest before conducting a peer review of a manuscript. Reviewers should decline to review if a potential conflict of interest is present.


Editorial staff employed by Radcliffe Group, editors-in-chief and guest editors, will not handle manuscripts where a potential conflict of interest exists.


Acknowledgements: The author(s) should acknowledge substantive contributions to the article, including receipt of financial assistance, materials and other resources.


Informed consent: Authors should include a statement in the manuscript that informed consent was obtained, if experimentation with human subjects was conducted. The privacy rights of human subjects must always be observed. For more information please read: https://www.radcliffecardiology.com/privacy-statement


Human and animal rights: If the work involves the use of animal or human subjects, the author should ensure that the work described has been carried out in accordance with the Code of Ethics of the World Medical Association(Declaration of Helsinki) for research involving humans or the EU Directive 2010/63/EU for animal experiments and/or ARRIVE guidelines for animal research.

1.8 References

All articles must be fully referenced. References must be numbered in order of the first mention. They must be indicated in the text by a number with the full list at the end of the article in numerical order. They must not be used to promote self-interests.
 

Journal Articles 
Journal abbreviations are used as per Medline. If there are more than three authors, list the first three followed by et al., unless there are four authors, in which case list all four. Details should be ordered as: Surname Initials. Article title. Journal name year;volume:page numbers. doi: [doi number]. PMID: [PMID number].


Example: Delpón E, Cordeiro JM, Núñez L, et al. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol 2008;1:209–18. https://doi.org/10.1161/CIRCEP.107.748103; PMID: 19122847.


Book Chapters
Example: Mansbach H. Sumatriptan: looking back and looking forward. In: Humphrey P, Ferari M, Olesen J (eds). The Triptans. New York: Oxford University Press, 2001;183–9.

2.0 Peer Review Process

We operate a double-blind peer-review process. All peer reviews are conducted within the Editorial Manager platform.
 

On submission, items submitted to the journal are assessed by the Editor-in-Chief to assess their suitability for inclusion. Items that are deemed unsuitable, fail a technical check or that are deemed more suitable for another journal are returned at this stage.
 

The Review Editor, following consultation with the Editor-in-Chief, Deputy Editors and/or a member of the Editorial Board, sends the manuscript for peer review. All peer reviews are conducted independently, treated confidentially and are double-blinded. We require a minimum of two independent peer reviews but will seek a third review where there are conflicting reports. The peer reviewers are selected on the basis of their expertise in the article subject matter and have no conflicts of interest. Peer reviewers are not part of the editorial staff and are independent of the article.


The peer review feedback is used to critically assess the quality of the article, to assess its suitability for inclusion in the journal and to ensure its credibility of scientific information.


Following review, manuscripts are either accepted without modification, accepted pending modification, or may require further revision, in which case the manuscripts may be returned to the author(s) to incorporate required changes, or may be rejected outright. Not all articles that are revised are subsequently accepted. The Editor-in-Chief reserves the right to accept or reject any proposed amendments.


Once the authors have revised a manuscript in accordance with the reviewers’ comments, the manuscript is returned to the reviewers to ensure the revised version meets their quality expectations. Once approved, the manuscript is sent to the Editor-in-Chief for final approval prior to publication. We aim to complete the peer review process with the average time from submission to the first decision within 6 weeks and submission to a final decision within 10 weeks.


It is our aim to ensure authors are notified of any rejection or retraction as soon as possible. An editor can reject an article at any time before publication, including after acceptance if there are concerns over the work. In the event that a journal is no longer published, access to all articles will be available via alternative platforms, such as PubMed Central, ESCI or Scopus.

3.0 Data Sharing Policy

Radcliffe is committed to an open science landscape, removing barriers from the sharing of research and the underlying data. This facilitates openness, transparency and reproducibility of research. All Radcliffe journals are open access, and we encourage our authors to share their research data. Research data refers to the information gathered, reviewed, analysed, generated or created and can be presented in a variety of formats including numerical, descriptive, aural, or visual. We encourage Radcliffe authors to:
 

  1. share your research data in a relevant public data repository, where this does not violate the protection of human subjects or other valid subject privacy concerns.
  2. include a data availability statement (DAS) that links to your data. Where the data cannot be shared, you should confirm why it is not possible to share the data within this statement.
  3. cite the data in your research.


As all of our journals operate under a double-blind peer-review process, if sharing your data, you will need to use a repository that includes an option to preserve your anonymity.


Authors are encouraged to share their data but not required to. The decision to publish will not be affected by whether or not authors share their research data.

3.1 Data Repositories

We advise authors to speak to your institutional librarian, funder or colleagues for guidance on choosing a repository that is relevant to your discipline. Alternatively, some useful resources for searching for a suitable repository are FAIRsharing and re3data.org, which provide a list of certified data repositories. Some general repositories that are not subject-specific include:
 

3.2 Data Availability Statement

As per the ICMJE recommendations data sharing statements should include:
 

  1. whether individual de-identified participant data (including data dictionaries) will be shared (“undecided” is not an acceptable answer);
  2. what data, in particular, will be shared;
  3. whether additional, related documents will be available (e.g., study protocol, statistical analysis plan, etc.);
  4. when the data will become available and for how long;
  5. by what access criteria data will be shared (including with whom, for what types of analyses, and by what mechanism).


The table below provides some template statements that you may use or adapt. You can find further guidance on how to compose this statement on the ICMJE recommendations website.


 

Availability of Data Template Statement
Data is openly available in a public repository (DOI provided) The data that support the findings of this study are openly available in [repository name e.g “figshare”] at http://doi.org/[doi], reference number [reference number].
Data openly available in a public repository (no DOI provided) The data that support the findings of this study are openly available in [repository name] at [URL], reference number [reference number].
Data derived from public domain resources The data that support the findings of this study are available in [repository name] at [URL/DOI], reference number [reference number]. These data were derived from the following resources available in the public domain: [list resources and URLs]
Embargo on data due to commercial restrictions The data that support the findings will be available in [repository name] at [URL / DOI link] following an embargo from the date of publication to allow for commercialization of research findings.
Data available on request due to privacy/ethical restrictions The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
Data subject to third party restrictions The data that support the findings of this study are available from [third party]. Restrictions apply to the availability of these data, which were used under license for this study. Data are available [from the authors / at URL] with the permission of [third party].
Data available on request from the authors The data that support the findings of this study are available from the corresponding author upon reasonable request.
Data sharing not applicable – no new data generated Data sharing is not applicable to this article as no new data were created or analyzed in this study.
Author elects to not share data Research data are not shared.
Data available in article supplementary material The data that supports the findings of this study are available in the supplementary material of this article.
Data sharing not applicable – no new data generated, or the article describes entirely theoretical research Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
3.3 Data Citation

Radcliffe supports the Force 11 Data Citation Principles, as such all publicly available datasets must be fully referenced in the reference list with an accession number or unique identifier such as a digital object identifier (DOI) using the following format and in line with the Radcliffe reference style:
 

[dataset]* Authors, Year, Title, Publisher (repository or archive name), accession number/DOI * The [dataset] tag will help us identify and tag the correct citation, but this will be removed prior to publication.


We protect an individual's data and will not publish any patient data that might identify an individual without their written consent. For detailed information on our data sharing policy please click here.

4.1 Proofs

All accepted manuscripts will be subject to editorial revisions for clarity, punctuation, syntax and conformity to house style.
 

Laid-out proofs will be sent to the corresponding author following the first stage of editing. Any requests for changes must be returned by the deadline given. Articles are considered final once an author approves the corrected proofs. Only minor changes can be made at the proofing stage; major changes will not be accepted.

5.0 Copyright, Permissions and Open Access

Articles published in JAPSC are open access, which means the content is freely available, immediately upon publication, without charge, and allows users to read, download, copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly. The author retains all non-commercial rights for articles published under the Creative Commons Attribution Non-commercial CC-BY-NC 4.0 license. 
After your manuscript is accepted the corresponding author will be asked to sign a mandatory copyright transfer agreement (CTA) to grant us permission to publish the manuscript under these terms.

 

Radcliffe Medical Media retains all commercial rights for articles herein unless otherwise stated. Permission to reproduce an article or any of its contents for commercial purposes, either in full or in part, should be sought from the publication's Publisher.


Authors are responsible for obtaining permission for all copyright material, including tables, figures and images. Evidence will need to be provided for all permissions granted.

5.1 Author Fees

To support open access publication costs, Radcliffe Cardiology and Radcliffe Vascular charge an Article Publication Charge (APC) to authors upon acceptance of an unsolicited paper, as follows:
 

Content Type Fee
Article £1,050 | €1,200 | $1,369
Case Report £787 | €870 | $970
Editorial No fee
Expert Opinion £787 | €870 | $970
Letter No fee
Meta-analysis £787 | €870 | $970

 

Members of the Asian Pacific Society of Cardiology will receive a 30% discount on the APC.

Submissions from the UK will be subject to VAT. A VAT registration number should be supplied if applicable. If you are not registered for VAT, your invoice will still have VAT added.
 

After manuscript acceptance, the corresponding author will be contacted, and an invoice will be sent. Accepted articles will not be published until payment has been received.

5.2 APC Waivers and Discounts

A 100% waiver is applicable under the following circumstances:
 

  • For all content solicited by Radcliffe Cardiology/Radcliffe Vascular.
  • For all letters and editorials submitted to the journal.
  • For all content submitted by an editorial board member.
  • If the corresponding author is from a low-income country (as defined by the World Bank).


A 50% waiver is applicable under the following circumstances:

  • If the corresponding author is from a lower-middle-income country (as defined by the World Bank).


A 25% waiver is applicable under the following circumstances:

  • If the corresponding author submits a paper within 12 months of completing their most recent peer review for a Radcliffe journal.


Discretionary waivers may also be considered.


Radcliffe Cardiology/Radcliffe Vascular remains dedicated to helping researchers to disseminate scientific information globally and is working to partner with individual institutions to offer full or partial APC discounts. If you are an institution looking to partner with us, or think your institution should, then please contact the Publishing Director.


To ensure editorial integrity, the waiver process is not handled by the managing editors. Authors should submit a waiver request during the electronic submission process.

5.3 Misconduct and malpractice

We take reasonable steps to identify and prevent the publication of papers where misconduct has occurred. In no case shall we as the publisher or our editors encourage or knowingly allow such misconduct to take place to published and unpublished papers. 
 

Our journals use similarity checking software to detect unoriginal material and to avoid plagiarism. Where duplication is highlighted, the concerns will be raised with the author.


We do not permit the manipulation of research data through data falsification or data fabrication. Where data falsification or fabrication is suspected, the concerns will be raised with the author.


We reserve the right to reverse decisions to accept a submission where we believe our editorial policies have been infringed and papers suspected of misconduct will not be considered for publication. We reserve the right to inform the author’s co-authors and/or institution/regulatory body when such instances occur.

5.4 Errors, Omissions and Retractions

We take strive to ensure the academic integrity of our journals and to ensure that all content is reproduced correctly. However, we cannot guarantee the accuracy, adequacy or completeness of the information and cannot be held responsible for any errors or omissions, or for the results obtained from the use thereof. Occasionally circumstances may arise were an article is published that must later be retracted or removed. We commit to retract, correct and apologise for any inaccuracies or misleading statements with due prominence through errata which are issued as needed. Any errors should be reported to the journal’s Managing Editor. In all cases, our archives at The British Library and the Agency for Legal Deposit Libraries retain all versions.

5.5 Advertising

Advertising is not permitted to influence editorial decisions. Advertisements cannot be carried by the journal that juxtapose editorial content on the same product. Adverts may appear at the front and back of a journal (never within text). Misleading adverts may be refused. 

5.6 Complaints & Appeals

Any complaints should be first directed to the Editorial Office/Managing Editor of the Journal in writing. If they are the subject of the complaint, please raise this with the Publishing Director. We as the Publisher will aim to deal with any complaints or allegations of misconduct as appropriately and as swiftly as possible. If not resolved satisfactorily, any complaints can be passed to the overseeing body or ombudsmen where one exists. Complaints may be referred to COPES within six months if it cannot be resolved through the journal's complaints procedure and only if it pertains to procedural complaints rather than editorial content.

5.7 Reprints

Reprints of all published articles are available to authors, institutions and commercial organisations. Reprints are published as they appear in the journal unless a correction is to be added. Please contact Rob Barclay at rob.barclay@radcliffe-group.com